Inadequate Use of Newer Treatments and Glycemic Control by Cardiovascular Risk and Sociodemographic Groups in US Adults with Diabetes in the NIH Precision Medicine Initiative All of Us Research Program
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inadequate Use of Newer Treatments and Glycemic Control by Cardiovascular Risk and Sociodemographic Groups in US Adults with Diabetes in the NIH Precision Medicine Initiative All of Us Research Program
Authors
Keywords
-
Journal
CARDIOVASCULAR DRUGS AND THERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-11-15
DOI
10.1007/s10557-022-07403-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Why Choose Between SGLT2 Inhibitors and GLP1-RA When You Can Use Both?
- (2021) Alice Y.Y. Cheng CIRCULATION
- Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019
- (2021) Rozalina G. McCoy et al. JAMA Network Open
- Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
- (2021) Su Jin Jeong et al. BMC Nephrology
- Contemporary National Patterns of Eligibility and Utilization of Novel Cardioprotective Anti‐hyperglycemic agents in Type 2 Diabetes
- (2021) Arash A Nargesi et al. Journal of the American Heart Association
- Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US
- (2021) Lauren A. Eberly et al. JAMA Network Open
- Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA
- (2021) HoJin Shin et al. DIABETES CARE
- Hypertension prevalence in the All of Us Research Program among groups traditionally underrepresented in medical research
- (2021) Paulette D. Chandler et al. Scientific Reports
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
- (2021) DIABETES CARE
- Envisioning a Better U.S. Health Care System for All: Coverage and Cost of Care
- (2020) Ryan Crowley et al. ANNALS OF INTERNAL MEDICINE
- Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits
- (2020) Yumin Gao et al. AMERICAN HEART JOURNAL
- The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program
- (2020) Clare Arnott et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
- (2020) Sandeep R. Das et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
- (2020) Guntram Schernthaner et al. Cardiovascular Diabetology
- Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D
- (2020) Colette DeJong et al. JAMA Internal Medicine
- The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus
- (2019) Alexia Piperidou et al. JOURNAL OF HYPERTENSION
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- The “All of Us” Research Program
- (2019) NEW ENGLAND JOURNAL OF MEDICINE
- Adoption of New Glucose-Lowering Medications in the U.S.—The Case of SGLT2 Inhibitors: Nationwide Cohort Study
- (2019) Rozalina G. McCoy et al. Diabetes Technology & Therapeutics
- Ensuring Access to Quality Health Care in Vulnerable Communities
- (2018) Jay Bhatt et al. ACADEMIC MEDICINE
- Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR)
- (2018) Suzanne V. Arnold et al. AMERICAN HEART JOURNAL
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
- (2018) Michael S. Kelly et al. POSTGRADUATE MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of ethnicity on HbA1c levels in individuals without diabetes: Systematic review and meta-analysis
- (2017) Gabriela Cavagnolli et al. PLoS One
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical and Patient-Related Variables Associated with Initiating GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Patients in Primary Care in Germany
- (2016) Qing Qiao et al. PLoS One
- Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences
- (2015) Linda A Gallo et al. Diabetes & Vascular Disease Research
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists
- (2015) Charles F Shaefer et al. POSTGRADUATE MEDICINE
- Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis
- (2015) Xiaoyan Song et al. Scientific Reports
- Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
- (2013) Louise E Robinson et al. BMJ Open
- Glycemic control among Latinos with type 2 diabetes: The role of social-environmental support resources.
- (2011) Addie L. Fortmann et al. HEALTH PSYCHOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started